ACTG 326: ALVAC HIV VACCINE IN CHILDREN BORN TO HIV INFECTED MOTHERS

ACTG 326：为感染 HIV 的母亲所生的孩子提供 ALVAC HIV 疫苗

• 批准号: 6264292
• 负责人: ELIZABETH G MCFARLAND
• 金额: $ 1.99万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264292
• 关键词: AIDS therapy; AIDS vaccines; HIV infections; Poxviridae; cellular immunity; clinical research; clinical trial phase I; cytotoxic T lymphocyte; drug screening /evaluation; helper T lymphocyte; human subject; human therapy evaluation; humoral immunity; immunoglobulin A; immunoglobulin G; infant human (0-1 year); lymphocyte proliferation; mucosal immunity; recombinant virus; vertical transmission; virus antigen; virus load

There are two specific aims. The two primary aims are 1) to determine the safety of live recombinant Canarypox ALVAC HIV vaccine in infants who are of indeterminate status born to HIV-infected women; 2) to evaluate humoral and cell-mediated responses including cytotoxic T cell and lympho- proliferative responses to HIV-specific antigens and non-HIV antigens in immunized infants. The two secondary aims are 1) to review changes in viral load over time in infants proven to be infected and absolute CD4 counts in all immunized infants; 2) to evaluate whether changes in HIV-specific IgG and IgA in the mucosal secretions can be detected.

有两个具体目标。两个主要目的是：1)确定重组金丝雀痘ALVAC活疫苗对HIV感染妇女所生的身份不确定婴儿的安全性；2)评估免疫婴儿对hiv特异性抗原和非hiv抗原的体液和细胞介导反应，包括细胞毒性T细胞和淋巴细胞增殖反应。这两个次要目的是：1)研究证实感染婴儿的病毒载量随时间的变化和所有免疫婴儿的绝对CD4计数；2)评估是否可以检测到粘膜分泌物中hiv特异性IgG和IgA的变化。